These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9120422)

  • 1. IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism.
    Tissingh G; Booij J; Winogrodzka A; van Royen EA; Wolters EC
    J Neural Transm Suppl; 1997; 50():31-7. PubMed ID: 9120422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
    Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders.
    Kugaya A; Fujita M; Innis RB
    Ann Nucl Med; 2000 Feb; 14(1):1-9. PubMed ID: 10770574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
    Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N
    Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM.
    Donnemiller E; Brenneis C; Wissel J; Scherfler C; Poewe W; Riccabona G; Wenning GK
    Eur J Nucl Med; 2000 Sep; 27(9):1410-4. PubMed ID: 11007526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
    Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
    Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Arnold G; Ott M; Trenkwalder C; Kirsch CM; Oertel WH
    Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SPECT imaging using [123I]beta-CIT and [123I]IBF in extrapyramidal diseases].
    Sasaki T; Amano T; Hashimoto J; Itoh Y; Muramatsu K; Kubo A; Fukuuchi Y
    No To Shinkei; 2003 Jan; 55(1):57-64. PubMed ID: 12649900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.